Abbonarsi

Repeat endoscopic submucosal dissection as salvage treatment for local recurrence of esophageal squamous cell carcinoma after initial endoscopic submucosal dissection - 14/06/22

Doi : 10.1016/j.gie.2022.02.043 
Jia-Qi Xu, MD 1, , Zhao-Chao Zhang, MD 1, , Wei-Feng Chen, MD 1, , Mei-Dong Xu, MD 1, Shi-Yao Chen, MD 1, Yun-Shi Zhong, MD 1, Yi-Qun Zhang, MD 1, Jian-Wei Hu, MD 1, Ming-Yan Cai, MD 1, Li-Qing Yao, MD 1, Ping-Hong Zhou, MD, FASGE 1, 2, , Quan-Lin Li, MD 1, 2
1 Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China 
2 Shanghai Collaborative Innovation Center of Endoscopy, Shanghai, China 

Reprint requests: Quan-Lin Li, MD, or Ping-Hong Zhou, MD, FASGE, Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, 180 FengLin Rd, Shanghai 200032, China.Endoscopy Center and Endoscopy Research InstituteZhongshan HospitalFudan University180 FengLin RdShanghai200032China

Abstract

Background and Aims

Local recurrence of esophageal squamous cell carcinoma (ESCC) after endoscopic resection does not have an established treatment. The efficacy and safety of repeat endoscopic submucosal dissection (ESD) for recurrent ESCC were determined in the study.

Methods

Forty-three consecutive patients with 45 locally recurrent superficial ESCC lesions undergoing repeat ESD and 909 first ESD lesions for propensity score matching (PSM) at Zhongshan Hospital between January 2011 and January 2020 were retrospectively enrolled. After PSM (1:2), operation-related parameters were compared between repeat ESD and first ESD. In the repeat ESD group, the Kaplan-Meier method and log-rank tests were used for identification of risk factors for local recurrence after repeat ESD.

Results

As compared with propensity score–matched first ESD, rates of complete resection (86.7% vs 97.8%, P = .02) and curative resection (86.7% vs 96.7%, P = .06) were lower and procedure duration (54.8 ± 21.7 minutes vs 46.2 ± 20.6 minutes, P = .67) and hospital stay (4.3 ± 1.8 days vs 2.9 ± 1.4 days, P = .25) were longer in the repeat ESD group. The en-bloc resection rate (93.3% vs 98.8%, P > .11) remained comparable. Adverse events including bleeding (4.4% vs 0%, P = .11), perforation (.0% vs .0%, P > .99), and stricture (6.7% vs 2.2%, P = .33) presented with no difference. The 5-year overall survival rate and recurrence-free survival rate for repeat ESD was 100% and 86.0%, respectively. Multiplicity was significantly associated with recurrence after repeat ESD (P = .01).

Conclusions

Repeat esophageal ESD showed favorable short- and long-term outcomes and thus provides an alternative choice for recurrent superficial ESCC.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : ESCC, ESD, LVI, PSM


Mappa


 DISCLOSURE: All authors disclosed no financial relationships. Research support for this study was provided by grants from theNational Key R&D Program of China(2019YFC1315800, P.-H. Zhou),National Natural Science Foundation of China(81873552, Q.-L. Li,82003074, J.-Q. Xu, and81670483, P.-H. Zhou),Shanghai Rising-Star Program(19QA1401900, Q.-L. Li),Major Project of Shanghai Municipal Science and Technology Committee(18ZR1406700, Q.-L. Li,19441905200, W.-F. Chen, and16DZ2280900, L.-Q. Yao), andShanghai Sailing Program of Shanghai Municipal Science and Technology Committee(2018YF1403700, J.-Q. Xu).
 DIVERSITY, EQUITY, AND INCLUSION: We worked to ensure gender balance in the recruitment of human subjects. We worked to ensure ethnic or other types of diversity in the recruitment of human subjects. One or more of the authors of this paper self-identifies as an under-represented gender minority in science. While citing references scientifically relevant for this work, we actively worked to promote gender balance in our reference list. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work
 If you would like to chat with an author of this article, you may contact Dr Li at li.quanlin@zs-hospital.sh.cn or Dr Zhou at zhou.pinghong@zs-hospital.sh.cn.


© 2022  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 96 - N° 1

P. 18 - luglio 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Role of functional luminal imaging probe in the management of postmyotomy clinical failure
  • Yervant Ichkhanian, Olaya Brewer Gutierrez, Sabine Roman, In Kyung Yoo, Andrew Canakis, Rishi Pawa, Kenneth Koch, Bailey Su, Michael Ujiki, Eva Alsheik, Tobias Zuchelli, Cyrus Piraka, Bachir Ghandour, Linda Zhang, Joshua A. Sloan, Mouen A. Khashab
| Articolo seguente Articolo seguente
  • Use of topical mineral powder as monotherapy for treatment of active peptic ulcer bleeding
  • Joseph J.Y. Sung, Sulleman Moreea, Harinder Dhaliwal, Dana C. Moffatt, Krish Ragunath, Terry Ponich, Alan N. Barkun, Ernst J. Kuipers, Robert Bailey, Fergal Donnellan, David Wagner, Keith Sanborn, James Lau

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.